GRTX
Galera Therapeutics, Inc.
Price Chart
Latest Quote
$0.09
-0.00 (-3.30%)
Current Price
| Previous Close | $0.09 |
| Open | $0.09 |
| Day High | $0.09 |
| Day Low | $0.09 |
| Volume | 28,201 |
Stock Information
| Shares Outstanding | 203.27M |
| Cash Equivalents | $5.50M |
| Net Income | $63.52M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $17.89M |
| P/E Ratio | 0.14 |
| EPS (TTM) | $0.64 |
| Exchange | OQB |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $12.91M |
| Income | $63.52M |
| Book/sh | $0.01 |
| Cash/sh | $0.03 |
| Employees | 3 |
Financial Ratios
| Quick Ratio | 4.82 |
| Current Ratio | 5.31 |
Returns & Margins
| ROA | -51.84% |
Ownership
| Insider Ownership | 49.36% |
| Institutional Ownership | 7.89% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -0.07 |
| P/B | 8.80 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.09 |
| SMA50 | $0.09 |
| SMA200 | $0.04 |
| RSI | 35.56 |
| ATR | 0.0050 |
| Shares Float | 57.40M |
| Short Float | 5.28% |
| Short Ratio | 1.16 |
| Volatility | 2.59 |
| Rel Volume | 0.72 |
Performance History
| Week | +1.15% |
| Month | -6.38% |
| Quarter | +95.56% |
| 6 Months | +282.61% |
| YTD | +282.61% |
| Year | +214.29% |
| 3 Years | -97.40% |
| 5 Years | -99.02% |
| 10 Years | -99.27% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-23 | $0.09 | 43,200 |
| 2026-06-22 | $0.09 | 28,800 |
| 2026-06-18 | $0.09 | 220,800 |
| 2026-06-17 | $0.09 | 3,000 |
| 2026-06-16 | $0.09 | 54,800 |
| 2026-06-15 | $0.09 | 212,900 |
| 2026-06-12 | $0.09 | 3,400 |
| 2026-06-11 | $0.09 | 10,500 |
| 2026-06-10 | $0.09 | 81,600 |
| 2026-06-09 | $0.09 | 39,900 |
| 2026-06-08 | $0.10 | 26,900 |
| 2026-06-05 | $0.09 | 160,200 |
| 2026-06-04 | $0.10 | 2,600 |
| 2026-06-03 | $0.10 | 33,600 |
| 2026-06-02 | $0.10 | 46,200 |
| 2026-06-01 | $0.10 | 107,500 |
| 2026-05-29 | $0.10 | 13,500 |
| 2026-05-28 | $0.10 | 17,900 |
| 2026-05-27 | $0.10 | 10,000 |
| 2026-05-26 | $0.10 | 74,900 |
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a biopharmaceutical company, focuses on the development of a portfolio of small molecule dismutase (SOD) mimetics to improve radiotherapy in cancer. The company's lead product is tilarginine that is in Phase 1/2 trial of a pan-inhibitor of nitric oxide synthase to treat patients with highly resistant forms of breast cancer, including metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC). It develops avasopasem manganese, a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC). The company was incorporated in 2012 and is based in Malvern, Pennsylvania.
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $11,414,000 | $11,571,000 | $7,194,000 |
| Total Expenses | $14,153,000 | $46,951,000 | $51,226,000 | $73,368,000 |
| Other Income Expense | $-5,561,000 | $-2,312,000 | $-1,000 | $-4,000 |
| Net Non Operating Interest Income Expense | $554,000 | $-9,819,000 | $-11,065,000 | $-7,162,000 |
| Interest Expense Non Operating | $0 | $11,414,000 | $11,571,000 | $7,194,000 |
| Operating Expense | $14,153,000 | $46,951,000 | $51,226,000 | $73,368,000 |
| General And Administrative Expense | $11,002,000 | $22,836,000 | $20,214,000 | $20,951,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Net Interest Income | $554,000 | $-9,819,000 | $-11,065,000 | $-7,162,000 |
| Interest Income | $554,000 | $1,595,000 | $506,000 | $32,000 |
| Normalized Income | $-13,457,171 | $-56,770,000 | $-62,221,001 | $-80,530,000 |
| Net Income From Continuing And Discontinued Operation | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Total Operating Income As Reported | $-20,160,000 | $-49,260,000 | $-51,226,000 | $-73,368,000 |
| Net Income Common Stockholders | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Net Income | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Net Income Including Noncontrolling Interests | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Net Income Continuous Operations | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Pretax Income | $-19,160,000 | $-59,082,000 | $-62,292,000 | $-80,534,000 |
| Special Income Charges | $-6,007,000 | $-2,309,000 | $0 | - |
| Interest Income Non Operating | $554,000 | $1,595,000 | $506,000 | $32,000 |
| Operating Income | $-14,153,000 | $-46,951,000 | $-51,226,000 | $-73,368,000 |
| Per Share | ||||
| Diluted EPS | $-0.34 | $-1.33 | $-2.30 | $-3.12 |
| Basic EPS | $-0.34 | $-1.33 | $-2.30 | $-3.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $-61,171 | $0 | $-1 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,579,000 | $-45,097,000 | $-50,606,000 | $-72,558,000 |
| Total Unusual Items | $-5,561,000 | $-2,312,000 | $-1,000 | $-4,000 |
| Total Unusual Items Excluding Goodwill | $-5,561,000 | $-2,312,000 | $-1,000 | $-4,000 |
| Reconciled Depreciation | $20,000 | $259,000 | $114,000 | $778,000 |
| EBITDA (Bullshit earnings) | $-19,140,000 | $-47,409,000 | $-50,607,000 | $-72,562,000 |
| EBIT | $-19,160,000 | $-47,668,000 | $-50,721,000 | $-73,340,000 |
| Diluted Average Shares | $54,633,215 | $44,549,285 | $27,086,664 | $25,789,458 |
| Basic Average Shares | $54,633,215 | $44,549,285 | $27,086,664 | $25,789,458 |
| Diluted NI Availto Com Stockholders | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Tax Provision | $-203,000 | $0 | $-70,000 | $0 |
| Other Special Charges | $2,868,000 | - | - | - |
| Impairment Of Capital Assets | $3,139,000 | $0 | - | - |
| Restructuring And Mergern Acquisition | $0 | $2,309,000 | $0 | - |
| Gain On Sale Of Security | $446,000 | $-3,000 | $-1,000 | $-4,000 |
| Research And Development | $3,151,000 | $24,115,000 | $31,012,000 | $52,417,000 |
| Selling General And Administration | $11,002,000 | $22,836,000 | $20,214,000 | $20,951,000 |
| Other Gand A | $11,002,000 | $22,836,000 | $20,214,000 | $20,951,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-143,669,000 | $-134,324,000 | $-112,320,000 | $-61,143,000 |
| Total Assets | $10,101,000 | $26,141,000 | $44,036,000 | $83,311,000 |
| Total Non Current Assets | $100,000 | $4,512,000 | $5,501,000 | $5,919,000 |
| Other Non Current Assets | $100,000 | $90,000 | $1,881,000 | $1,957,000 |
| Goodwill And Other Intangible Assets | $0 | $3,139,000 | $3,139,000 | $3,139,000 |
| Current Assets | $10,001,000 | $21,629,000 | $38,535,000 | $77,392,000 |
| Other Current Assets | $282,000 | $620,000 | $6,888,000 | $6,175,000 |
| Prepaid Assets | $795,000 | $2,752,000 | - | $6,175,000 |
| Receivables | $635,000 | $0 | - | - |
| Other Receivables | $635,000 | - | - | - |
| Cash Cash Equivalents And Short Term Investments | $8,289,000 | $18,257,000 | $31,597,000 | $71,217,000 |
| Cash And Cash Equivalents | $8,289,000 | $18,257,000 | $4,266,000 | $19,859,000 |
| Other Intangible Assets | - | $2,258,000 | $2,258,000 | $2,258,000 |
| Restricted Cash | - | $0 | $50,000 | $0 |
| Debt | ||||
| Total Debt | $0 | $1,250,000 | $44,000 | $302,000 |
| Long Term Debt And Capital Lease Obligation | $0 | $1,117,000 | $0 | $44,000 |
| Current Debt And Capital Lease Obligation | - | $133,000 | $44,000 | $258,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $153,770,000 | $157,326,000 | $153,217,000 | $141,315,000 |
| Total Non Current Liabilities Net Minority Interest | $152,104,000 | $152,369,000 | $139,838,000 | $128,380,000 |
| Other Non Current Liabilities | $151,049,000 | $151,049,000 | $139,635,000 | $128,063,000 |
| Derivative Product Liabilities | $1,055,000 | $0 | - | - |
| Non Current Deferred Liabilities | $0 | $203,000 | $203,000 | $273,000 |
| Non Current Deferred Taxes Liabilities | $0 | $203,000 | $203,000 | $273,000 |
| Current Liabilities | $1,666,000 | $4,957,000 | $13,379,000 | $12,935,000 |
| Payables And Accrued Expenses | $1,618,000 | $4,703,000 | $10,680,000 | $10,639,000 |
| Payables | $1,275,000 | $1,375,000 | $3,581,000 | $5,044,000 |
| Accounts Payable | $1,275,000 | $1,375,000 | $3,581,000 | $5,044,000 |
| Equity | ||||
| Common Stock Equity | $-148,041,000 | $-131,185,000 | $-109,181,000 | $-58,004,000 |
| Preferred Stock Equity | $4,372,000 | - | - | - |
| Total Equity Gross Minority Interest | $-143,669,000 | $-131,185,000 | $-109,181,000 | $-58,004,000 |
| Stockholders Equity | $-143,669,000 | $-131,185,000 | $-109,181,000 | $-58,004,000 |
| Retained Earnings | $-456,363,000 | $-437,406,000 | $-378,324,000 | $-316,102,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $-22,000 | $-14,000 |
| Other Equity Adjustments | - | - | $-22,000 | $-14,000 |
| Other | ||||
| Ordinary Shares Number | $75,462,390 | $54,392,170 | $28,510,066 | $26,458,767 |
| Share Issued | $75,462,390 | $54,392,170 | $28,510,066 | $26,458,767 |
| Tangible Book Value | $-148,041,000 | $-134,324,000 | $-112,320,000 | $-61,143,000 |
| Invested Capital | $-148,041,000 | $-131,185,000 | $-109,181,000 | $-58,004,000 |
| Working Capital | $8,335,000 | $16,672,000 | $25,156,000 | $64,457,000 |
| Capital Lease Obligations | $0 | $1,250,000 | $44,000 | $302,000 |
| Total Capitalization | $-143,669,000 | $-131,185,000 | $-109,181,000 | $-58,004,000 |
| Additional Paid In Capital | $308,247,000 | $306,167,000 | $269,137,000 | $258,086,000 |
| Capital Stock | $4,447,000 | $54,000 | $28,000 | $26,000 |
| Common Stock | $75,000 | $54,000 | $28,000 | $26,000 |
| Preferred Stock | $4,372,000 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $0 | $1,117,000 | $0 | $44,000 |
| Current Capital Lease Obligation | $0 | $133,000 | $44,000 | $258,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $48,000 | $121,000 | $2,655,000 | $2,038,000 |
| Current Accrued Expenses | $343,000 | $3,328,000 | $7,099,000 | $5,595,000 |
| Goodwill | $0 | $881,000 | $881,000 | $881,000 |
| Net PPE | $0 | $1,283,000 | $481,000 | $823,000 |
| Accumulated Depreciation | $0 | $-459,000 | $-1,701,000 | $-1,587,000 |
| Gross PPE | $0 | $1,742,000 | $2,182,000 | $2,410,000 |
| Leases | $0 | $46,000 | $270,000 | $264,000 |
| Machinery Furniture Equipment | $0 | $484,000 | $471,000 | $471,000 |
| Buildings And Improvements | $0 | $1,212,000 | $43,000 | $296,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $27,331,000 | $51,358,000 |
| Other Properties | - | - | $1,398,000 | $1,379,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,145,000 | $-44,907,000 | $-43,451,000 | $-68,241,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,145,000 | $-44,848,000 | $-43,426,000 | $-67,958,000 |
| Cash Flow From Continuing Operating Activities | $-12,145,000 | $-44,848,000 | $-43,426,000 | $-67,958,000 |
| Operating Gains Losses | $-404,000 | $-72,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $-46,000 | $27,293,000 | $23,994,000 | $5,238,000 |
| Cash Flow From Continuing Investing Activities | $-46,000 | $27,293,000 | $23,994,000 | $5,238,000 |
| Capital Expenditure | - | $-59,000 | $-25,000 | $-283,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,223,000 | $29,299,000 | $3,808,000 | $7,941,000 |
| Financing Cash Flow | $2,223,000 | $31,496,000 | $3,889,000 | $66,707,000 |
| Cash Flow From Continuing Financing Activities | $2,223,000 | $31,496,000 | $3,889,000 | $66,707,000 |
| Net Common Stock Issuance | $2,223,000 | $29,299,000 | $3,808,000 | $7,941,000 |
| Common Stock Issuance | $2,223,000 | $29,299,000 | $3,808,000 | $7,941,000 |
| Net Other Financing Charges | - | - | - | $57,500,000 |
| Other | ||||
| End Cash Position | $8,289,000 | $18,257,000 | $4,316,000 | $19,859,000 |
| Beginning Cash Position | $18,257,000 | $4,316,000 | $19,859,000 | $15,872,000 |
| Changes In Cash | $-9,968,000 | $13,941,000 | $-15,543,000 | $3,987,000 |
| Proceeds From Stock Option Exercised | $0 | $2,197,000 | $81,000 | $1,266,000 |
| Net Investment Purchase And Sale | $0 | $27,352,000 | $24,019,000 | $5,521,000 |
| Sale Of Investment | $0 | $49,995,000 | $83,910,000 | $77,500,000 |
| Purchase Of Investment | $0 | $-22,643,000 | $-59,891,000 | $-71,979,000 |
| Net Business Purchase And Sale | $-50,000 | $0 | - | - |
| Purchase Of Business | $-50,000 | $0 | - | - |
| Net PPE Purchase And Sale | $4,000 | $-59,000 | $-25,000 | $-283,000 |
| Sale Of PPE | $4,000 | $0 | - | - |
| Purchase Of PPE | $0 | $-59,000 | $-25,000 | $-283,000 |
| Change In Working Capital | $-2,128,000 | $-2,927,000 | $17,000 | $-2,627,000 |
| Change In Other Current Liabilities | $-38,000 | $-104,000 | $-258,000 | $-307,000 |
| Change In Other Current Assets | $89,000 | $1,932,000 | $330,000 | $-246,000 |
| Change In Payables And Accrued Expense | $-4,474,000 | $-8,511,000 | $658,000 | $-1,052,000 |
| Change In Accrued Expense | $-3,058,000 | $-6,305,000 | $2,121,000 | $-951,000 |
| Change In Payable | $-1,416,000 | $-2,206,000 | $-1,463,000 | $-101,000 |
| Change In Account Payable | $-1,416,000 | $-2,206,000 | $-1,463,000 | $-101,000 |
| Change In Prepaid Assets | $2,295,000 | $514,000 | $2,529,000 | $-1,022,000 |
| Change In Receivables | $0 | $3,242,000 | $-3,242,000 | - |
| Other Non Cash Items | $3,843,000 | $11,414,000 | $11,571,000 | $7,194,000 |
| Stock Based Compensation | $2,545,000 | $5,560,000 | $7,164,000 | $7,231,000 |
| Asset Impairment Charge | $3,139,000 | $0 | - | - |
| Deferred Tax | $-203,000 | $0 | $-70,000 | $0 |
| Deferred Income Tax | $-203,000 | $0 | $-70,000 | $0 |
| Depreciation Amortization Depletion | $20,000 | $259,000 | $114,000 | $778,000 |
| Depreciation And Amortization | $20,000 | $259,000 | $114,000 | $778,000 |
| Gain Loss On Investment Securities | $-452,000 | - | - | - |
| Gain Loss On Sale Of PPE | $48,000 | $-72,000 | $0 | - |
| Net Income From Continuing Operations | $-18,957,000 | $-59,082,000 | $-62,222,000 | $-80,534,000 |
| Change In Other Working Capital | - | - | $-3,242,000 | - |
Fetched: 2026-02-02